Quick Summary
• Conexeu Sciences, a preclinical-stage regenerative tissue platform company, debuted on Nasdaq, framing the public listing as a milestone for its mission of “Architecting Bioregeneration” and for the development of a platform designed to support the biological conditions needed to restore lost or damaged tissue. “At Conexeu, we believe regenerative medicine requires more than incremental improvement;…
Additional Context
Conexeu Sciences, a preclinical-stage regenerative tissue platform company, debuted on Nasdaq, framing the public listing as a milestone for its mission of “Architecting Bioregeneration” and for the development of a platform designed to support the biological conditions needed to restore lost or damaged tissue.
“At Conexeu, we believe regenerative medicine requires more than incremental improvement; it requires a fundamentally different foundation,” said Miles D. Harrison, President and CEO of Conexeu. “We believe we are building the biological architecture for a new generation of regenerative medicine designed not simply to replace what has been lost, but to help the body restore itself. Becoming a public company we believe strengthens our ability to continue advancing the science, infra